Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Allorion Therapeutics›
News
AddedFeb 17, 2024
UpdatedJul 2, 2026
Allorion Therapeutics

Allorion Therapeutics

Allorion Therapeutics: Developing small molecule drugs for cancer and autoimmune diseases globally.

HQ
Natick, MA, US
Founded
2020
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Latest News About Allorion Therapeutics

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor

Avenzo Therapeutics

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor

Avenzo announces FDA clearance of IND for AVZO-023 (ARTS-023), novel CDK4 selective inhibitor from Allorion partnership. Potential...

May 21, 2025

Avenzo Therapeutics announces global license of AVZO-021 (ARTS-021), a potentially best-in-class clinical stage CDK2 inhibitor from Allorion Therapeutics

PR Newswire

Avenzo Therapeutics announces global license of AVZO-021 (ARTS-021), a potentially best-in-class clinical stage CDK2 inhibitor from Allorion Therapeutics

Avenzo Therapeutics gains global license for ARTS-021 / AVZO-021, highly potent and selective CDK2 isoform-specific inhibitor from Allorion...

Jan 4, 2024

Allorion Therapeutics announces exclusive option and global license agreement for novel preclinical-stage EGFR L858R allosteric inhibitor program with AstraZeneca

PR Newswire

Allorion Therapeutics announces exclusive option and global license agreement for novel preclinical-stage EGFR L858R allosteric inhibitor program with AstraZeneca

Allorion grants AstraZeneca exclusive option and global license for novel preclinical EGFR L858R allosteric inhibitor program for oncology....

Jan 2, 2024

Allorion Therapeutics announces first patient dosed in phase 1/2 study of ARTS-021, a potential best in class CDK2 inhibitor, for advanced or metastatic solid tumors

PR Newswire

Allorion Therapeutics announces first patient dosed in phase 1/2 study of ARTS-021, a potential best in class CDK2 inhibitor, for advanced or metastatic solid tumors

First patient dosed in Phase 1/2 trial (NCT05867251) of ARTS-021 (CDK2 inhibitor) in US for advanced or metastatic solid tumors. Open-label...

Oct 5, 2023

Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing

PR Newswire

Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing

Allorion announces $50M Series B co-led by INCE Capital and Qiming Venture Partners, with participation from TF Capital, Long River...

Mar 9, 2023

Next-generation Precision Medicine Company Allorion Therapeutics Completes Series A Financing Round

PR Newswire

Next-generation Precision Medicine Company Allorion Therapeutics Completes Series A Financing Round

$40M Series A led by Qiming Venture Partners, participated by IDG Capital, Octagon Capital, Firstred Capital, and Elikon Venture. Existing...

Nov 24, 2021